Similar articles

• [Spinal muscular atrophy: a hexosaminidase A deficiency phenotype].

  Kawanami T, Kato T. Kawanami T, et al. Ryoikibetsu Shokogun Shirizu. 1999;(27 Pt 2):379-81. Ryoikibetsu Shokogun Shirizu. 1999. PMID: 10434678 Review. Japanese. No abstract available.
• [Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease].

  Peleg L, Gazit E, Goldman B, Akstein E. Peleg L, et al. Harefuah. 1995 Dec 1;129(11):475-80. Harefuah. 1995. PMID: 8846957 Review. Hebrew. No abstract available.
• [Tay-Sachs disease (beta-hexosaminidase alpha-chain deficiency)].

  Okada S, Taniike M. Okada S, et al. Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):394-6. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9645090 Review. Japanese. No abstract available.
• [Biosynthesis and biodegradation of GM2 ganglioside].

  Hirabayashi Y, Kasakura H, Matsumoto M. Hirabayashi Y, et al. Tanpakushitsu Kakusan Koso. 1984 Sep;29(9):708-22. Tanpakushitsu Kakusan Koso. 1984. PMID: 6240072 Review. Japanese. No abstract available.
• Diagnosis of Tay-Sachs disease using [3H]N-acetylneuraminic acid labelled GM2 ganglioside as substrate.

  Poulos A, Holding J, Carey WF. Poulos A, et al. Clin Chim Acta. 1982 Apr 23;120(3):331-40. doi: 10.1016/0009-8981(82)90374-6. Clin Chim Acta. 1982. PMID: 6210469